Seattle, United States
The iCAP is designed to use standardized cells as biosensors to detect and respond to signals in patient blood, overcoming the issue of low abundance blood biomarkers. Additionally, the company utilizes machine learning tools to predict the disease state of patients based on the gene expression responses of the cells. This approach transforms the complex task of identifying and detecting low abundance blood biomarkers into the established practice of measuring cell culture responses in vitro.
PreCyte Inc's vision extends to the development of pan-cancer iCAP panels for cancer screening, with the goal of improving patient outcomes. Presently, the company is actively involved in developing iCAPs for the early detection of lung cancer and Alzheimer's disease.
Established in 2014, PreCyte Inc operates within the biotechnology and healthcare industries with a focus on pioneering innovative solutions for disease detection and diagnosis.
